CRC Research Update — September 04, 2026
Today's colorectal cancer research highlights
Curated CRC research — accessible, accurate, actionable
The CRC Digest
Friday, September 04, 2026
IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.
CRC Research Update
-
SCREENING
Early-Onset Colorectal Cancer Incidence Accelerates Through 2023SEER data show early-onset CRC incidence accelerated during 2019-2023 with an annual percent change of 8.3%, while incidence among adults 65 and older declined. Black patients more often presented with stage IV disease (33.9% vs 29.3%) and had lower 3-year overall survival (67.3% vs 76.2%) compared to White patients. (Am J Surg)
-
SCREENING
Blood-Based CRC Screening Tests Show Promise but Have Key LimitationsThree blood-based CRC screening tests (Epi proColon, Shield, and the Freenome test) have completed large validation studies, but all show low sensitivity for advanced precancerous lesions, low rates of follow-up colonoscopy after an abnormal test, and concerns about cost-effectiveness. (Gastrointest Endosc Clin N Am)
-
SCREENING
Meta-Analysis Examines Fecal Immunochemical Test AccuracyA systematic review and meta-analysis evaluated the diagnostic accuracy of quantitative fecal immunochemical tests (FIT) for colorectal cancer and advanced neoplasm, examining variations in performance by sex, geographic region, study design, FIT platform, and positivity threshold. (Cancer Res Treat)
-
RESEARCH
Nanoparticle Platform Targets Radioresistance in KRAS-Mutant CRCResearchers developed sulfasalazine-loaded hafnium oxide nanoparticles (HfO2@SAS) to overcome radiotherapy resistance in KRAS-mutant colorectal cancer by targeting the SLC7A11/GPX4 pathway and inducing ferroptosis (a form of cell death). (Biomaterials)
Today's research underscores the urgent need to address rising early-onset CRC rates and improve screening access across all populations. Stay informed and discuss screening options with your care team.
Get CRC research intelligence delivered weekly — free.
SubscribeCRC Digest
Not Medical Advice
The CRC Digest provides research summaries for informational and educational purposes only. This is not medical advice. Always consult your healthcare provider before making any decisions about your care.
Content is curated with AI assistance and reviewed by the editorial team.
Browse Past Issues · Read our full disclaimer · Manage subscription
Useful? Forward it to a colleague. Every topic in this briefing has a live research dossier — trajectory and evidence — at Signal Bureau.
Got this from a colleague? Subscribe here — we only ever add readers who sign themselves up.
Evolution Accelerator, Inc. (dba Evolution Labs) · 3941 Park Dr., Suite 20341, El Dorado Hills, CA 95762
You are receiving this because you subscribed to CRC Digest (self-serve signup)
Unsubscribe — honored promptly, no login required. · Privacy policy · Manage or delete your data